|

Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

RECRUITINGEarly 1Sponsored by Noxopharm Limited
Actively Recruiting
PhaseEarly 1
SponsorNoxopharm Limited
Started2025-07-14
Est. completion2026-02
Eligibility
Age18 Years – 64 Years
Healthy vol.Accepted

Summary

The goal of this study is to investigate the safety and tolerability of the topical application of SOF-SKN in healthy volunteers. The study will be divided into part 1 and part 2. Part 1, is a single ascending dose (SAD) design, while Part 2 is a multiple ascending dose (MAD) design.

Eligibility

Age: 18 Years – 64 YearsHealthy volunteers accepted
Inclusion Criteria:

* Healthy Volunteers 18 to 64 years.
* Participants with Fitzpatrick skin type I to IV.
* Participants must have a back surface area of at least 24 × 30 cm to accommodate two - 10 × 30 cm application areas with a 4 cm separation between them.
* No Allergies.
* Contraception.
* Must be willing to abstain from the use of moisturizers and other topical applications on the back 24 hours prior and for the duration of the study.

Exclusion Criteria:

* Allergic constitution.
* Within 72 hours of the start of study treatment, the use of antihistamines or use of topical drugs at the application site.
* Hair removing interventions including laser treatment, shaving and waxing in the target area within 1 week before Screening.
* Hypertrichosis on the back; no tattoos that cover greater than 30% of the back surface area.
* Presence of an inflammatory dermatosis (including, but not limited to, atopic dermatitis, eczema, psoriasis, extensive acne), and/or suntan/burn that could interfere with the test field evaluation.
* Non-inflammatory skin lesions and changes (including, but not limited to, hyperpigmentation, multiple naevi, tattoos, blemishes, birthmarks, abrasions, ulcers, eschar, and/or scabs) present in the target area on the back that could interfere with the test field evaluation.
* Any history of or presence of in situ melanoma and non-melanoma skin cancer within the last 3 years.
* Any other skin disease or other visible skin condition noted on physical examination which in the Investigator's opinion might interfere with the evaluation of the test field reaction.

Conditions2

Cutaneous Lupus ErythematosusLupus

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.